1. Introduction {#S8}
===============

Antipsychotic medication is the mainstay of effective management of schizophrenia. The first-generation 'conventional' antipsychotic drugs are predominantly antagonists of dopamine D2 receptors, and are effective against most positive symptoms, but have high rates of extrapyramidal side effects ([@R58]). The second-generation or 'atypical' antipsychotics differ from previous antipsychotic agents in their lower affinity for dopamine- and other neuro-receptors (5-HT2A, adrenergic, acetylcholine, and histamine receptors) ([@R48], [@R42]) with a reduced profile of extrapyramidal side-effects ([@R58]) but with comparable rates of adverse events such as sedation and weight gain ([@R48]). Despite these pharmacodynamic differences, all antipsychotics cross the brain--blood barrier to target receptors distributed in the brain, with a clinical efficacy starting in the first days of treatment and accumulating over time ([@R1]). The effect of antipsychotics on brain function starts immediately and can be detected after a single dose using molecular imaging techniques ([@R32]). There is recent evidence indicating rapid structural remodeling and short-term neural plasticity with acute D2 receptor blockade ([@R88]). The reversibility of these findings and their clinical meaning, in particular in relation to the long-term outcomes of schizophrenia are unknown ([@R76]). However, they provide converging evidence that antipsychotic treatment, even acutely, can significantly impact brain structure and function. This can be particularly relevant to the longitudinal course of the illness and partially account for the observed dynamic brain changes associated with the disorder ([@R35]). A number of longitudinal structural Magnetic Resonance Imaging (MRI) studies have found progressive brain changes in adults with schizophrenia during the initial years after the onset of the illness ([@R37], [@R41]). The extent of progressive brain tissue decrease in patients (−0.5% per year) has been estimated as twice that of healthy controls (−0.2% per year) ([@R37]). These progressive brain changes have been associated with poorer clinical outcomes ([@R34]; [@R10]; [@R90]), more negative symptoms, and a decline in neuropsychological performance, although not consistently ([@R89]). Currently, it is not clear when these structural brain changes occur and how they develop over time. However, studying individuals at clinical high risk of developing psychosis ([@R23]) has allowed the investigation of structural brain alterations before the onset of the illness. MRI studies addressing structural alterations in individuals at enhanced risk for psychosis have been recently summarized, confirming that some abnormalities are already present during the prodromal phase ([@R24]) and may be predictive of later transition to psychosis ([@R81]). Despite evidence suggesting early brain changes in psychosis, the specific role played by antipsychotic treatment is strongly debated. Some studies have indicated that higher cumulative dose of antipsychotic medication intake is not associated with brain volume changes, and may even be associated with less prominent volumetric changes ([@R37]). Conversely, recent investigations in first-episode patients showed increased antipsychotic exposure was associated with brain volume reduction ([@R35]); and that this association was stronger than illness-related effects. In addition studies from other groups have indicated a differential protective effect of atypical vs. typical antipsychotic on brain volume changes in schizophrenia ([@R58]).

Besides the potential effect of antipsychotics on brain structure, other factors should be considered when discussing progressive brain changes in schizophrenia. Two commonly investigated clinical variables in the imaging literature are duration of illness (DOI) and severity of illness. A plethora of imaging data are now available at different stages of the illness ([@R65]) and a recent voxel-based meta-analysis has directly tested the hypothesis that patients with chronic schizophrenia have more extensive brain abnormalities observed in the same regions as non-psychotic relatives, subjects at high risk for psychosis and first-episode samples ([@R12]). Subtraction analyses between these groups confirmed that gray matter abnormalities observed in the prodromal phases of schizophrenia become more extensive through first-episode and chronic illness, confirming the significant role played by illness duration on imaging results ([@R12]). Severity of signs and symptoms is also associated with different brain alterations in schizophrenia. For example MRI studies conducted in antipsychotic-naïve subjects reported negative correlations between positive psychotic symptoms and volumes of temporal areas, and between negative symptoms and volume of fronto-cerebellar areas ([@R91]). In particular the association between gray matter reductions in the temporal areas and severity of auditory hallucinations has been confirmed in several MRI studies as well as in extensive voxel-based meta-analyses ([@R59]).

Given the above three confounders, the available qualitative reviews addressing progressive brain changes in schizophrenia have yielded inconclusive results ([@R93]; [@R64]; [@R80]; [@R62]). There are no studies investigating the consistency and magnitude of progressive volumetric changes in schizophrenia in a quantitative meta-analysis, controlling at the same time for the above confounders. In the present study we first sought to examine at a meta-analytical level whether schizophrenia is characterized by progressive brain changes as compared to healthy controls. We then aimed to investigate the effect of potential moderators affecting brain structure such as illness duration, illness severity, and antipsychotic treatment.

2. Methods {#S9}
==========

The details of the research protocol are appended in the [supplementary protocol (S1)](#SD1){ref-type="supplementary-material"}.

2.1. Selection procedures {#S10}
-------------------------

### 2.1.1. Search strategies {#S11}

A systematic search strategy was used to identify relevant studies. Three independent researchers (RS, PFP, SB) conducted a three-step literature search. First, a PubMed and Embase search was performed to identify putative longitudinal MRI studies in schizophrenia. The search was conducted up to end of April 2012, with no time span specified for date of publication. The following search terms were used: "MRI" OR "neuroimaging" AND "schizophrenia" AND "antipsychotic" AND "longitudinal" NOT "review". In a second step the reference lists of the articles included in the review were manually checked for any studies not identified by the computerized literature search. In the final step, 5 journals with the highest impact factor in the field of psychiatry were additionally searched for potential articles of interests. There was no language restriction, although all the included papers were in English.

### 2.1.2. Selection criteria {#S12}

Studies were included if they met the following criteria: (a) were reported in an original paper in a peer-reviewed journal, (b) had involved subjects with DSM-IV, DSM-III-R or ICD-10 schizophrenia (c) had employed volumetric MRI in a longitudinal design (baseline/follow-up study); (d) had evaluated relative contributions of at least one potential moderator (illness duration, antipsychotic treatment, illness severity) of brain volume change. The latter was defined as cumulative exposure of antipsychotics during the inter-scan interval and computed as chlorpromazine equivalents ([@R35]) (see [S1](#SD1){ref-type="supplementary-material"} paragraph 9). When standardized diagnosis of psychotic subjects was not clearly defined, the study was excluded. Voxel Based Morphometry (VBM), Cortical Pattern Matching, Diffusion Tensor Imaging, Tractography or other techniques that do not report absolute brain volumes were not included. When there were two or more studies from the same center we contacted the authors to clarify whether there was overlap in the respective samples (if several articles dealt with the same population, we selected the article with the largest sample). When studies did not report data to compute the chlorpromazine equivalents or other significant data we carefully contacted the respective authors to collect the individual scores and avoid biases in the literature search.

### 2.1.3. Recorded variables {#S13}

The variables recorded from each article included in the meta-analysis were: sample size, year of publication, gender (proportion of females), mean age of participants, duration of follow-up, duration of illness, type of antipsychotic treatment, daily dose of antipsychotic at the follow-up MRI (chlorpromazine equivalents), previous exposure to antipsychotics, brain volumes (see below), severity of psychotic symptoms (see below). To achieve a high standard of reporting we have adopted 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA) guidelines ([@R60]) (see [Fig. 1](#F1){ref-type="fig"}).

### 2.1.4. Extraction and standardization of psychometric rating scales {#S14}

There are several scales to measure psychotic symptoms used in studies with schizophrenia patients. Most commonly the Positive and Negative Symptom Scale (PANSS), and the Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS), and Scale for Assessment of Negative Symptoms (SANS) have been used. There is high correlation among both positive and negative scale totals across these tools ([@R47]) with good inter-rater and test-retest reliability ([@R53]). We extracted total PANSS, BPRS and SAPS + SANS scores from included studies. Each item of the SAPS and SANS is rated on a six point scale (0--5) and BPRS and PANSS on a seven point scale (1--7). Extracted total scores were transformed to a total score with a baseline of zero, in line with previous studies ([@R79])(see [S1](#SD1){ref-type="supplementary-material"}). To investigate the baseline psychotic symptoms in included studies we calculated mean per-item score by dividing the total score by 30 in PANSS, by 18 in BPRS and by 50 in SAPS + SANS. All included studies reported improvement on psychometric score during follow-up and we calculated it as percentage of baseline per-item score ([@R2]). The details of clinical variables used in the meta-analysis are described in the [supplementary material S1](#SD1){ref-type="supplementary-material"}, paragraph 8.

### 2.1.5. Quality assessment {#S15}

The quality of the studies was assessed using an item-checklist constructed specifically for the review and similar to the previously published quality assessment ([@R68]). The recorded variables were assessed in terms of precision, directness and consistency of the data. The categories scored in the quality assessment are listed in the [table S2](#SD1){ref-type="supplementary-material"} with the range min 0 and max 2 points. The code of the range was developed a priori and modified after the first run of quality assessment (see [S1](#SD1){ref-type="supplementary-material"}). The disagreements were discussed between the authors and the consensus was put in the table. Quality assessment was conducted in the following categories: (1) study design -- random blind, open or case--control, the role of the funding and sample size; (2) demographic and clinical characteristics -- clearly reported inclusion and exclusion criteria, substance abuse, included control group, gender, race, IQ, duration of the illness and previous antipsychotic medication; (3) results -- reported drop-out rates, psychopathological ratings, statistical thresholds, ROI reliability. The included studies were rated according to the sum of the points and characterized as high quality (above 80% of the maximal sum of points), moderate-high (60--79%), moderate (40--59%), moderate-low (20--39%), and low quality studies (below 19%)(see more details in [Tables S2 and S3](#SD1){ref-type="supplementary-material"}).

2.2. Statistical analysis {#S16}
-------------------------

Data were entered into an electronic database and analyzed with a quantitative meta-analytical approach using Comprehensive Meta-Analysis (CMA) Software version 2 (Biostat, Inc., Englewood, NJ, USA). CMA software employs the same computational algorithms used by the Cochrane collaborators to weight studies by the inverse variance method ([@R7]). The primary effect size measure was the difference in brain volumes between patients and controls at baseline and at the end of follow-up (see [S1](#SD1){ref-type="supplementary-material"}). Meta-analyses were conducted when at least three studies reported the volume of a common brain region. We were thus able to analyze the following regions: gray matter volume (GMV), white matter volume (WMV), cerebrospinal fluid (CSF) and whole brain volume (WBV) as a sum of gray matter plus white matter volume ([@R16]). Most included studies reported volumetric data (WBV and/or GMV and/or WMV) including the volume of cerebellum. For studies where global volumes did not include cerebellar volume, we either present the data received directly from the author ([@R90]) or marked them if the authors did not respond ([@R82]; [@R84]; [@R6]; [@R35]) ([Table 1](#T1){ref-type="table"}) and adjusted our analysis accordingly (sensitivity analysis, see below). We also analyzed lateral ventricle volumes (LV) and the caudate nuclei volumes (Cd), defined as the sum of the left and right nuclei caudate. After completing a meta-analysis of progressive brain changes in patients and controls (at baseline and follow-up) we specifically tested the effect of putative moderator factors: cumulative antipsychotic exposure, duration of illness and illness severity.

The effect size was estimated by calculating Hedges' unbiased g. For the cross-sectional analysis, negative values reflected less gray matter volumes in the patients as compared to healthy controls. For the longitudinal analysis, negative values reflected brain volumes reductions at follow-up as compared to baseline. To limit risk of false positive (type I) errors arising from multiple comparisons we adjusted *p* \< 0.05 by dividing α with the number of meta-analyses conducted. The *Q* statistic was used to determine between-group differences. To determine whether categorical factors (i.e. substance abuse) modified the progressive brain changes, subgroup analyses were performed ([@R68]). The influence of continuous moderator variables (antipsychotic exposure, duration of illness and illness severity and study duration) was tested using meta-regression analyses. Meta-regressions (fixed effect models) were performed when at least seven independent studies were available for the outcome of interest. The slope of meta-regression (β-coefficient: direct (+) or inverse (−)) of the regression line indicates the strength of a relationship between moderator and outcome. The confounding effect of potential outliers on the meta-regression was controlled with the Cook's distance test ([@R14]).

Heterogeneity among study point estimates was assessed with the *Q* statistic ([@R68]) with magnitude of heterogeneity being evaluated with the *I*^2^ index ([@R50]). For homogeneous data, we calculated the global effect size, using a fixed effect model. In the absence of significant heterogeneity, the use of a fixed effect model is legitimate and may provide greater statistical power than the random effect model ([@R83]). For heterogeneous data we employed random effects models which are more conservative than fixed-effect models, and appear to better address heterogeneity between studies and study populations, allowing for greater flexibility in parsing effect size variability ([@R15]). Studies with negative results are less likely to be published than studies with statistically significant results. The possibility of small publication biases in the present study was examined by visually inspecting funnel plots and applying the regression intercept of [@R21]. In this way we assessed whether there was a tendency for selective publication of studies based on the nature and direction of their results. In addition, we used the fail-safe procedure ([@R66]), to generate a number of unpublished studies that would be needed to move estimates to a non significant threshold. In case of publication bias we adopted the 'trim and fill' method, which aims both to identify and correct for funnel plot asymmetry arising from publication bias ([@R20]). To assess the robustness of the results, we performed sensitivity analyses by sequentially removing each study and rerunning the analysis. We also conducted a separate analysis excluding studies with quality ratings in the lowest third to determine if potential methodological weaknesses influenced meta-analytic estimates. Finally we conducted a sensitivity analysis excluding the studies that had not included cerebellar volumes.

3. Results {#S17}
==========

3.1. Database {#S18}
-------------

The initial literature search uncovered 116 potential studies. Out of the 65 full-text assessed studies, 35 did not meet inclusion criteria and were excluded. The final database comprised 30 original independent studies published between 1994 and 2012. The overall sample was of 1046 schizophrenia patients and 780 controls for a median duration of follow-up of 72.4 weeks (range 4--520). The details of the literature search are described in the PRISMA flowchart, while the characteristics of the included and excluded studies are detailed in [Table 1](#T1){ref-type="table"} and [supplementary material S4](#SD1){ref-type="supplementary-material"} respectively.

3.2. Baseline differences in brain volumes {#S19}
------------------------------------------

After correcting for multiple comparisons, we found significant baseline volumetric differences in the WBV, with patients showing reduced volumes as compared to controls (*p* = 0.002, [Table 2](#T2){ref-type="table"}). Conversely, patients showed enlarged LV volumes as compared to controls (*p* \< 0.001). There were trend-level differences in the reduced GMV, which however did not survive correction for multiple comparisons. Increased cerebrospinal fluid was observed in patients but this occurred in the presence of publication bias (see below). There were no significant baseline differences in WMV or caudate nucleus (Cd) volume.

3.3. Longitudinal difference in brain volumes {#S20}
---------------------------------------------

When WBV at the end of the follow-up was compared with the baseline values, there was an overall decrease, which however was not statistically significant for both the patient (*p* = 0.339) and control (*p* = 0.333) groups (between groups difference *p* = 0.923, [Table 3](#T3){ref-type="table"}). Similarly, there were non-significant volume decreases in the Cd for both patients (*p* = 0.913) and controls (*p* = 0.160) groups (between groups difference *p* = 0.318).

Significant longitudinal volumetric changes were observed in the GMV and LV. The first showed significant volumetric decreases in patients (*p* = 0.002) but not in controls (*p* = 0.094). The differences in the patient group survived correction for multiple comparisons. There was a significant between group differences in longitudinal GMV changes (*Q* = 5.974, *p* = 0.044; [Table 3](#T3){ref-type="table"}). There were significant LV increases in the patient (*p* = 0.002) but not in the control group (*p* = 0.102). The differences in the patient group survived correction for multiple comparisons and a significant between-group difference was detected (*Q* = 9.566, *p* = 0.029, [Table 3](#T3){ref-type="table"}).

WMV and CSF showed non-significant increases at follow-up as compared to baseline across both patients (WMV *p* = 0.998, CSF *p* = 0.970) and control (WMV *p* = 0.108, CSF *p* = 0.391) groups (WMV between groups differences *p* = 0.262, CSF between groups differences *p* = 0.185).

3.4. Effects of moderators {#S21}
--------------------------

The details of antipsychotic treatment, symptoms severity, and duration of illness are given in [supplementary Tables S5 and S6](#SD1){ref-type="supplementary-material"}). Meta regression analyses for the selected moderators (cumulative exposure to antipsychotic medication during follow-up time, psychotic symptoms change over follow-up and duration of illness) were tested for both GMV and LV changes in the patient group. Longitudinal GMV decreases in patients were associated with higher cumulative exposure to antipsychotic over time (n of studies = 8 ([@R82]; [@R49]; [@R61]; [@R17]; [@R90]; [@R6]; [@R35]; [@R5]), sample = 629 schizophrenia subjects, β = −0.013, CI 95% from −0.033 to −0.001, *Q* = 8.598, *p* = 0.048, [Fig. 2a](#F2){ref-type="fig"}) but not with psychotic symptoms change (n of studies = 7 ([@R82]; [@R49]; [@R61]; [@R17]; [@R90]; [@R73]; [@R5]), sample = 418 schizophrenia subjects, *p* \> 0.05, [Fig. 2b](#F2){ref-type="fig"}) or DOI (n of studies = 9 ([@R82]; [@R49]; [@R61]; [@R17]; [@R90]; [@R73]; [@R6]; [@R35]; [@R5]), sample = 645 schizophrenia subjects, *p* \> 0.05, [Fig. 2c](#F2){ref-type="fig"}). Longitudinal LV changes in patients were not associated with cumulative exposure to antipsychotics (n of studies = 10 ([@R11]; [@R22]; [@R69]; [@R74]; [@R34]; [@R82]; [@R49]; [@R63]; [@R90]; [@R6]), sample = 533 schizophrenia subjects, *p* \< 0.05) or DOI (n of studies = 11 ([@R22]; [@R69]; [@R74]; [@R34]; [@R82]; [@R19]; [@R49]; [@R95]; [@R63]; [@R90]; [@R6]), sample = 542 schizophrenia patients, *p* \> 0.05, [Fig. 3](#F3){ref-type="fig"}). Because of missing data (n of studies \<7) it was not possible to conduct a meta-regression between LV changes and psychotic symptoms changes in patients. There was no significant confounding effect for study duration on the longitudinal GMV changes (β = −0.0006, CI 95% from −0.001 to 0.001, *Z* = −1.772, *p* = 0.096). Although studies with a longer duration tended to detect larger LV enlargements as compared to studies with a short follow-up, this effect was non significant (β = 0.001, CI 95% from −0.001 to 0.002, *Z* = 1.413, *p* = 0.158).

3.5. Publication bias, heterogeneity, sensitivity analysis {#S22}
----------------------------------------------------------

As also shown in [Table 2](#T2){ref-type="table"}, the fail-safe number in the baseline analysis surpassed the number of actual studies by a factor 2.25 (GMV) up to a factor 4 (LV). Conversely, both the fail-safe number and the Egger's regression test indicated publication bias for CSF. Significance of Hedge's g did not survive after adjustment by the Trim and Fill method. Fail-safe numbers were generally larger in the longitudinal analysis. Egger's regression test did not indicate publication bias here and significance of effect sizes did not change after adjustment by the Trim and Fill method. Heterogeneity was low and non-significant in the cross-sectional analysis. The presence of statistically significant heterogeneity of low magnitude in the longitudinal analysis accounted for the exploratory investigations of potential moderator factors. Quality analysis showed that most of the included studies were of high or moderate quality (13.3% high and 73.3% moderate scores). Removing studies with quality ratings in the lowest third did not affect the point estimates by more than 8.5%. The results of the sensitivity analysis excluding studies that did not include cerebellar volumes, did not affect the overall baseline meta-analytical estimates more than 7% (GMV: 7%, WMV 4%, WBV 6%).

4. Discussion {#S23}
=============

The present meta-analysis investigated longitudinal gray matter changes in schizophrenia addressing the impact of illness duration, severity of psychotic symptoms and antipsychotic treatment. Thirty longitudinal MRI studies were included with final database of 1046 schizophrenia patients and 780 controls. At the baseline cross-sectional analysis, the patients showed significant WBV reductions and enlarged LV volumes as compared to controls but no abnormalities in GMV, WMV, CSF and Cd. Longitudinally, there were progressive GMV decreases and LV enlargements in the schizophrenia group while no significant changes were observed in control group. The higher the cumulative exposure to antipsychotic treatment the greater the GMV decreases in the patient group over follow-up time, while no significant effects were observed for illness duration or severity of symptoms.

Our systematic literature search uncovered a large database of 30 longitudinal MRI studies with antipsychotic administration. The large sample size combined with the absence of significant publication biases (except for CSF), low heterogeneity between studies, strict quality control and careful sensitivity analysis yielded a robust meta-analytical approach. We first conducted a cross-sectional analysis to address putative brain changes prior the initiation of the longitudinal MRI studies. Patients compared to controls had reduced WBV and enlarged LV with trend-level reductions in GMV, which did not survive multiple comparisons. A recent meta-analysis has addressed the cross-sectional brain volume changes in medicated schizophrenia patients; small to medium meta-analytical differences were confirmed in WBV (effect size = −0.17), GMV (−0.43) and LV (0.45) ([@R31]). In line with these findings, our cross-sectional analysis detected similar small to medium magnitude in the observed effect sizes: WBV (−0.25), GMV (−0.19), LV (0.31). However, these findings are based on cross-sectional designs and thus it is not possible to establish whether these alterations are secondary to previous antipsychotic treatments, illness duration or illness severity or a mixture of these or other confounding factors. Furthermore, as moderate atrophy of gray matter structures has been observed during normal aging ([@R51]) it is not clear whether similar dynamic alterations occur in healthy individuals.

To address these caveats we have conducted a meta-analytical comparison of WMV, GMV, CSF, WBV, LV, and Cd volumes from longitudinal studies in patients with schizophrenia vs. controls. We found progressive GMV reductions and LV enlargements in schizophrenia patients but not in healthy controls. Previous evidence has indicated that the annualized percentage volume changes in schizophrenia were −0.59% for GMV, and +0.36% for LV ([@R65]). The overall effect sizes for our longitudinal LV increases over follow-up time were small to medium: 0.21 in patients and 0.13 in controls. LV increases (approximately 130% the size of normal controls ([@R96])) are the earliest (identified by CT imaging in 1976) ([@R40]) and the most consistent volumetric abnormalities reported in schizophrenia ([@R41]), in up to 66% of available studies ([@R75]). We found no modulating effect of antipsychotic treatment or illness duration on progressive LV increases. Previous works suggested that LV enlargement is globally interrelated with GMV diminution ([@R36]). In line with this hypothesis we also uncovered longitudinal GMV reductions. Overall the effect size for the longitudinal GMV decreases over follow-up time was again small to medium: −0.25 and in the patient and −0.14 in the control group. Interestingly, the magnitude of progressive GMV decreases was very close to that observed for LV increases, in line with the hypothesis that progressive cortical shrinkage over time might largely explain LV increases. To test that there was a pathological difference in the longitudinal progression of brain changes we compared the magnitude of changes between the patient and control group. The between-groups difference in GMV and LV was statistically significant, indicating that the schizophrenia patients, compared to matched healthy controls, showed pathological progressive GMV decreases and LV increases. However, it is important to note that the lack of significant progressive changes in controls may be a matter of power and variability in included groups. Similarly, our group-level analysis cannot exclude that the observed pathological changes can occur only in a subset of schizophrenia patients ([@R3]).

Given the longitudinal design we then tested the potential effect of the above confounders in the schizophrenia group: antipsychotic cumulative dose during the MRI study, overall duration of illness, and changes of illness severity i.e. psychotic symptoms during the MRI study. The core finding of the present meta-analysis is that longitudinal GMV decreases in schizophrenia patients were associated with higher cumulative exposure to antipsychotic over time, while no effects were observed for duration of illness and severity of symptoms. To our best knowledge this is the first time there is meta-analytical longitudinal evidence for a significant correlation of antipsychotic treatment and progressive GMV changes in a large sample of schizophrenia subjects (*n* = 629). Our longitudinal result reinforces the previous cross-sectional evidence indicating that GMV loss was more pronounced in patients using a higher dose of antipsychotic medication (atypical but not typical) at time of scanning ([@R31]). The merit of our investigation is that rather than using the current dose of antipsychotic medication we employed the cumulative exposure to antipsychotic treatment during follow up, accounting for the exact duration of longitudinal exposure. Our result of structural changes associated with antipsychotic treatment is in line with functional findings indicating that antipsychotics influence neural activity in psychosis, even in the short-term period ([@R25]; [@R52]). The putative mechanism of action of antipsychotics on GMV is unknown and can only be inferred in vivo from animal studies. Chronic exposure of macaque monkeys to haloperidol or olanzapine was associated with a 10--18% lower glial cell number in the gray matter ([@R44]). A recent investigation tested the hypothesis that chronic treatment with antipsychotic drugs is associated with a decrease in brain cortical volume, whereas treatment with mood stabilizers is associated with an increase in cortical brain volume ([@R92]). Chronic haloperidol treatment induced decreases cortical GMV; in contrast, chronic lithium treatment induced increases in GMV. Following drug withdrawal, haloperidol-induced changes in brain volumes normalized ([@R92]). However, some studies showed GMV continues to decline in the same patients following discontinuation of antipsychotics ([@R6]). Such a finding reinforces the hypothesis that schizophrenia may be associated with progressive morphologic changes to which antipsychotic drugs may contribute but are not the sole cause ([@R3]). However, the present meta-analysis contradicts explanations that progressive brain losses are simply a correlate of poor clinical outcome, for which antipsychotic medication is only considered any epiphenomenon. In fact, in a recent multimodal voxel-based meta-analysis combining functional and structural MRI studies we showed that anterior cingulate and insula were influenced by exposure to antipsychotics: GMV abnormalities in these regions were significantly more severe in medicated as compared to drug naïve patients ([@R70]). As GMV alterations were already observed in meta-analyses of antipsychotic-naïve first-episode subjects ([@R27]), as well as in subjects at high clinical risk for psychosis ([@R24]), antipsychotics may target regions of key pathology in early psychosis, without necessarily causing these alterations ([@R70]). Consequently, we speculate that progressive brain changes in schizophrenia may be related to a combination of antipsychotic effects as well as illness progression-reflected in concurrent GMV reduction and LV enlargements ([@R36]). There are limitations to consider in the present study. First, meta-analyses usually carry on the methodological limitations of the individual studies included in their database. Older studies may be characterized by small sample sizes and overall poor quality control ([@R78]). When reporting whole brain volume some studies did and others did not included cerebellar volume in their data. We have controlled for this issue in our analysis. Importantly, cerebellar volume tends to be conserved over disease progression showing no significant differences over time ([@R3]) or are (not significantly) mirroring the pattern of the cerebral GM volume ([@R90]). We thus conclude that cerebellar volume, remaining unchanged over time, is not contributing to the longitudinal brain changes we detected. It is also important to note that we could not test the hypothesis that the changes in brain volume are nonlinear (the biggest at the beginning of the illness), as indicated by recent studies ([@R3]). Other methodological issues such as potential role of different scanners used, their upgrades, and software used in calculating brain volume change ([@R18]) could have influenced the results as well. However, to address this potential problem we have conducted a careful quality assessment and used the sum of scores in our analysis, uncovering no significant changes on the principal point estimates. Nonetheless, the pattern of volumetric changes in the brain vary with age: in young adults gray matter declines whilst white matter increases, while in older adults these measures both decline with age. In addition aging has a differential effect on regional brain in males and females ([@R29]). These sources of variability were not integrated in our analysis, but should be considered when interpreting our results. Additionally, there are potential alternative factors that may account for the association between brain volume and medication and which were difficult to control in our meta-analysis. In particular, our approach to quantify moderator variables, (e.g. medication taken during the follow-up period calculated in CPZ equivalents, or difficulty standardizing symptom measures across different scales) were based on assumptions that could differ from the ideal situation where raw individual patient data would be available to analyze. Another limitation underlying volumetric MRI meta-analyses can be that the individual studies usually rely on ROI approaches, which are manually traced. The manual tracing of ROIs, as compared to automated methods such as VBM, can introduce significant heterogeneity in the anatomical definition of brain areas introducing biases in significance of the results reported. In general, ROI analyses can also be affected by publication biases: researchers could perform several exploratory analyses but report only those which yielded significant results ([@R38]; [@R71]). Additionally, because of limited data available, we were unable to test all our research hypotheses. In particular we were unable to test whether LV changes were longitudinally associated with psychopathological i.e. PANSS changes in schizophrenia patients. Furthermore, we were unable to test the correlation between antipsychotic treatment and DOI and consequently assess the "independent" effects of antipsychotic treatment on brain volume changes. Finally, it is important to note that association is not causation and thus our findings of significant GMV decreases being correlated with cumulative exposure to antipsychotic treatments should be interpreted cautiously. In particular, multifactorial association implicating several alternative causal factors could potentially underlie our core findings. In other words, antipsychotic treatment may not be the only factor associated to longitudinal GMV decreases in schizophrenia. This is supported by progressive brain changes are already present before the onset and may in particular occur during transition of psychosis in antipsychotic-naïve subjects ([@R67]; [@R9]; [@R57]; [@R8]). Moreover, as we did not assess effects of conventional vs. atypical antipsychotics we cannot comment on potential differential and modulating effects on progression ([@R94]; [@R49]; [@R37]). Other potential confounders factors ([@R13]) such as the genetic modulation of progressive brain changes ([@R4]) or the role played by early cognitive deficits ([@R26]; [@R45]) or substance abuse ([@R72]; [@R54]) on gray matter changes should become subject of investigation by future original studies.

5. Conclusions {#S24}
==============

Schizophrenia is characterized by progressive gray matter volume decreases and lateral ventricular volume increases. Some of these neuroanatomical alterations may be correlated with antipsychotic treatment.
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======================
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![Meta-regression analysis: (a) progressive GMV changes and cumulative exposure to antipsychotics (β = −0.013, CI 95% from −0.033 to −0.001, *Q* = 8.598, *p* = 0.048); (b) progressive GMV changes and duration of illness (DOI, β = 0.001, CI 95% from −0.001 to 0.001, *p* = 0.653); (c) progressive GMV changes and psychotic symptoms change over follow-up time (β = 0.002, CI 95% from −0.011 to 0.016, *p* = 0.732). The size of the circle reflects the sample size of the study. Negative vaules on the y axis indicate brain volume reductions at follow-up as compared to baseline. Cumulative exposure to antipsychotics unit was defined in Chlorpromazine Equivalent per day (CPZ-EQ/d) multiplied by the duration of the medication treatment in days (for details see [Supplementary material](#SD1){ref-type="supplementary-material"} study protocol para. 9). Change in psychotic symptom unit: percentage of baseline per item score (positive values indicate improvement of symptoms at follow-up as compared to baseline; for details see [supplementary materials](#SD1){ref-type="supplementary-material"} section 8).](nihms557652f2){#F2}

![Meta-regression analysis showing no significant (*p* \> 0.05) correlations between: progressive LV volume changes and duration of illness (DOI) within the schizophrenia patients. The size of the circle reflects the sample size of the study. Positive values on the y axis reflect brain volume increases at follow-up as compared to baseline.](nihms557652f3){#F3}

###### 

Longitudinal magnetic resonance imaging studies of schizophrenia subjects and antipsychotic exposure included in the meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author & year                       Brain volumetric data\                                                                  Follow-up duration   Type of\        Previous antipsychotic\   Substance\   Schizophrenia patients   Healthy controls                                                   
                                      used in analysis                                                                                             antipsychotic   medication                abuse                                                                                                    
  ----------------------------------- --------------------------------------------------------------------------------------- -------------------- --------------- ------------------------- ------------ ------------------------ ------------------ ------- ------- ------- ----- --------- ------- -------
  Arango 2012 ([@R5])                 WBV, GMV, WMV, CSF                                                                      104.8                12.00           MIX                       Y (96)       N                        25                 15.50   2.00    28.00   94    15.30     1.50    67.00

  Boonstra 2011 ([@R6])               WBV, GMV[\*](#TFN2){ref-type="table-fn"}, WMV[\*](#TFN2){ref-type="table-fn"}, LV, NC   57.27                8.55            ATYP                      Y (100)      Y                        8 FE AF            27.97   8.24    25.00   20    27.97     5.63    33.30

                                                                                                                              54.00                0.84            ATYP                      Y (100)      Y                        8 FE               29.56   5.72    25.00                           

  Chakos 1994 ([@R11])                LV, NC                                                                                  72.00                .               TYP                       Y (27.5)     N                        29                 25.20   6.30    41.30   10    30.50     4.90    20.00

  Crespo-Facorro 2008 ([@R17])        WBV, GMV, WMV, LV, NC                                                                   54.60                4.60            TYP                       NA           Y                        18 Hal             29.76   7.88    38.90   38    Matched   .       31.60

                                                                                                                              55.30                4.20            ATYP                      NA           Y                        18 Olan            28.00   5.09    27.80   .     .                 .

                                                                                                                              53.70                3.50            ATYP                      NA           Y                        16 Risp            24.99   5.96    18.70   .     .                 .

  DeLisi 2004 ([@R19])                LV                                                                                      520.00               .               MIX                       Y            NA                       26                 26.80   7.08    34.60   20    25.50     .       40.00

  Frazier 1996 ([@R22])               LV, NC                                                                                  104.00               .               Clo/MIX                   Y            NA                       8                  15.10   2.30    13.00   8     15.40     3.10    12.50

  Garver 2005 ([@R28])                WMV, CSF                                                                                4.00                 .               TYP                       Y            N                        6                  32.20   14.80   33.00   7     29.00     9.00    28.60

                                                                                                                              4.00                 .               ATYP                      Y            N                        13                 31.60   10.20   31.00   .     .         .       .

  Gur 1998 ([@R30])                   WBV                                                                                     119.20               48.80           MIX                       N (100)      NA                       20 FE              29.20   8.00    42.50   17    31.90     8.90    23.50

                                      WBV                                                                                     119.20               48.80           MIX                       Y (100)      NA                       20 Ch              29.20   8.00    42.50   .     .         .       .

  Heitmiller 2004 ([@R33])            NC                                                                                      120.80               .               ATYP                      N            NA                       14                 26.30   6.80    50.00   14    26.70     11.30   50.00

  Ho 2011 ([@R35])                    GMV[\*](#TFN2){ref-type="table-fn"}                                                     374.40               202.80          MIX                       Y (86)       Y                        211                26.30   7.60    28.00   .     .         .       .

  Ho 2003 ([@R34])                    WBV                                                                                     171.00               83.20           MIX                       Y (55)       NA                       73                 24.50   4.67    27.00   23    26.90     1.60    34.80

  James 2004 ([@R39])                 WBV                                                                                     125.84               82.68           Cloz/ATYP                 Y (70)       NA                       9 M                17.70   1.70    .       9 M   15.70     2.00    .

                                                                                                                              88.92                27.04           Cloz/ATYP                 Y (38)       .                        7 F                15.30   1.50    .       7 F   16.40     2.10    .

  Keshavan 1994 ([@R43])              NC                                                                                      43.57                                TYP                       N            NA                       11                 .       .       .       .     .         .       .

  Lang 2004 ([@R46])                  NC                                                                                      56.00                17.10           ATYP                      Y (100)      N                        10                 35.30   8.80    30.00   23    23.30     7.40    47.80

                                                                                                                              52.10                6.90            ATYP                      Y (100)      N                        14                 23.70   3.30    28.60   .     .         .       .

                                                                                                                              42.20                12.10           ATYP                      Y (100)      N                        13                 25.60   8.20    23.10   .     .         .       .

  Lieberman 2005 ([@R49])             WBV, GMV, LV                                                                            52.00                .               TYP                       Y (67.1)     N                        79                 24.11   4.64    10.00   62    25.53     4.13    35.50

                                                                                                                              52.00                .               ATYP                      Y (76.8)     N                        82                 23.60   4.64    21.00                           

  Massana 2005 ([@R55])               NC                                                                                      9.00                 .               ATYP                      N            NA                       11                 23.00   4.00    27.00   .     .         .       .

  McClure 2008 ([@R56])               NC                                                                                      12.00                .               ATYP/Cloz                 Y            N                        10                 36.70   7.70    10.00   .     .         .       .

  Molina 2005 ([@R61])                WBV, GMV, WMV                                                                           102.40               39.60           ATYP                      N (100)      N                        49                 25.60   4.00    31.00   11    28.40     6.20    54.50

                                                                                                                              114.80               47.20           Clo                       Y            N                        29Ch               31.00   5.90                                    

  Nakamura 2007 ([@R63])              WMV, LV                                                                                 72.40                46.40           ATYP                      Y            N                        17 FE              24.70   7.00    17.70   26    23.60     4.10    15.40

  Puri 2001 ([@R61])                  LV                                                                                      30.90                6.20            MIX                       Y            N                        24                 28.47   8.45    .       12    27.92     6.14    .

  Reig 2009 ([@R73])                  GMV, WMV, CSF                                                                           104.00               .               Cloz/ATYP                 Y            N                        21                 15.70   1.70    23.80   34    15.20     1.40    38.20

  Saijo 2001 ([@R74])                 LV                                                                                      520.00               .               NA                        NA           N                        18                 37.50   8.90    50.00   12    37.10     4.20    41.70

  Scheepers 2001 ([@R77])             WBV, NC                                                                                 24.00                .               CLOZ                      Y (100)      N                        29                 35.23   10.34   30.80   .     .         .       .

  Sporn 2003 ([@R82])                 WBV[\*](#TFN2){ref-type="table-fn"}, GMV[\*](#TFN2){ref-type="table-fn"}, LV            176.80               72.80           MIX                       NA           N                        39                 15.00   2.30    38.50   43    14.80     2.20    37.20

  Takahashi 2009 ([@R84])             WBV[\*](#TFN2){ref-type="table-fn"}                                                     105.04               39.52           MIX                       Y            N                        23 FE              21.60   3.50    30.40   26    25.60     9.10    42.30

                                                                                                                              125.32               50.44           MIX                       Y            N                        11Ch               32.70   7.60    9.00    .     .         .       .

  Tauscher-Wisniewski 2005 ([@R85])   NC                                                                                      12.00                .               ATYP                      N (100)      NA                       14                 22.60   3.7     21.43   37    25.80     6.20    40.50

  Tauscher-Wisniewski 2002 ([@R86])   NC                                                                                      260.00               .               MIX                       Y (47)       NA                       15                 23.00   6.20    33.30   10    29.40     8.60    30.00

  Taylor 2005 ([@R87])                NC                                                                                      4.00                 .               MIX                       N            N                        11                 34.70   12.40   .       11    26.80     6.60    .

  van Haren 2008 ([@R90])             WBV, GMV, WMV[\*](#TFN2){ref-type="table-fn"}, LV                                       260.00               .               MIX                       Y            Y                        96                 32.22   11.10   27.00   113   35.28     12.30   32.70

  Whitworth 2005 ([@R95])             LV                                                                                      132.10               41.60           MIX                       NA           NA                       21 FE              25.00   4.80    0.00    20    31.50     4.90    0.00

                                                                                                                              171.10               63.40           MIX                       NA           NA                       17Ch               28.40   4.00    0.00    .     .         .       .
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Abbreviations*: AN, antipsychotic naïve; ATYP, atypical antipsychotic; Clo, clozapine; Ch, chronic; CSF, cerebrospinal fluid; F, female; FE, first episode; GMV, gray matter volume; Hal, haloperidol; LV, lateral ventricle; M, male; MIX, both typical and atypical antipsychotics; n, amount of individuals; N, no; NA, not announced; NC, caudate nucleus; Ola, olanzapine; Ris, risperidone; TYP, typical antipsychotic; WBV, whole brain; WMV, white matter volume; Y, yes;

volumetric data were presented without cerebellar volume.

###### 

Meta-analyses of baseline volumetric differences between schizophrenia patients and healthy controls. Negative values of Hedge's g indicate reduced volume in patients vs. controls.

  Brain region   N    SCZ   C     Hedge's *g*   *Z* score   *p*      Test for Heterogeneity   FSN                                       ERT      Trimm and Fill                                          
  -------------- ---- ----- ----- ------------- ----------- -------- ------------------------ ----------------------------------------- -------- ---------------- ------- ---- ------- -------- -------- --------
  *WBV*          11   581   429   −0.252        −0.414      −0.091   −3.063                   0.002[\*](#TFN4){ref-type="table-fn"}     13.561   26.26            0.194   27   0.411   −0.252   −0.414   −0.091
  *GMV*          8    399   382   −0.192        −0.343      −0.041   −2.493                   0.013                                     3.635    3.7              0.821   18   0.111   −0.192   −0.343   −0.041
  *WMV*          6    199   261   −0.012        −0.294      0.269    −0.087                   0.931                                     8.717    42.64            0.121   0    0.393   −0.012   −0.294   0.269
  *CSF*          3    60    98    0.451         0.088       0.813    1.434                    0.045                                     2.173    7.90             0.337   3    0.069   0.325    −0.037   0.686
  *LV*           11   549   347   0.309         0.144       0.467    4.046                    \<0.001[\*](#TFN4){ref-type="table-fn"}   12.084   17.25            0.279   44   0.139   0.309    0.144    0.467
  *Cd*           9    192   171   0.116         −0.107      0.339    1.020                    0.308                                     8.589    6.85             0.378   0    0.592   0.116    −0.107   0.339

WBV, whole brain volume; GMV, grey matter volume; WMV, white matter volume; CSF, cerebrospinal fluid; LV, lateral ventricules; Cd, Caudate nucleus; N = number of studies included in each meta-analysis; SCZ, number of patients with schizophrenia; C, number of controls;

Surviving correction for multiple comparisons (*p* = 0.008);

FSN, Fail Safe Number; ERT, Egger's Regression Test.

###### 

Meta-analyses of longitudinal volumetric differences between schizophrenia patients and healthy controls. Negative values of Hedge's g indicate reduced volume at follow-up vs baseline.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Brain region   N    Group   Hedge's *g*   *Z* score   *p*      Between\        FSN                                     ERT     Trim and Fill                                  
                                                                 groups effect                                                                                                  
  -------------- ---- ------- ------------- ----------- -------- --------------- --------------------------------------- ------- --------------- ---- ------- -------- -------- --------
  *WBV*          12   CTRL    −0.069        −0.208      0.070    −0.969          0.333                                   0.009   0.923           0    0.662   −0.069   −0.208   0.070

                      SCZ     −0.060        −0.183      0.063    −0.956          0.339                                                                        −0.060   −0.183   0.063

  *GMV*          9    CTRL    −0.143        −0.293      0.008    −1.555          0.094                                   5.974   0.044           21   0.742   −0.143   −0.293   0.008

                      SCZ     −0.249        −0.399      −0.093   −3.154          0.002[\*](#TFN7){ref-type="table-fn"}                                        −0.249   −0.399   −0.093

  *WMV*          8    CTRL    0.148         −0.032      0.328    1.608           0.108                                   1.259   0.262           0    0.341   0.148    −0.032   0.328

                      SCZ     0.001         −0.184      0.184    0.002           0.998                                                                        0.001    −0.184   0.184

  *CSF*          3    CTRL    0.199         −0.256      0.654    0.858           0.391                                   1.759   0.185           0    0.351   0.199    −0.256   0.654

                      SCZ     0.007         −0.339      0.352    0.037           0.970                                                                        0.007    −0.339   0.352

  *LV*           12   CTRL    0.129         −0.025      0.283    1.637           0.102                                   9.566   0.029           34   0.178   0.129    −0.025   0.283

                      SCZ     0.207         0.075       0.339    3.067           0.002[\*](#TFN7){ref-type="table-fn"}                                        0.207    0.075    0.339

  *Cd*           13   CTRL    −0.149        −0.357      0.059    −1.405          0.160                                   0.996   0.318           0    0.409   −0.149   −0.357   0.059

                      SCZ     −0.010        −0.183      0.164    −0.109          0.913                                                                        −0.010   −0.183   0.164
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

WBV, whole brain volume; GMV, grey matter volume; WMV, white matter volume; CSF, cerebrospinal fluid; LV, lateral ventricules; Cd, Caudate nucleus; N = number of studies included in each meta-analysis; SCZ, number of patients with schizophrenia; C, number of controls;

Surviving correction for multiple comparisons (p = 0.008);

FSN, Fail Safe Number; ERT, Egger's Regression Test.
